Increase in lung cancer resection rate linked to increased investment in thoracic surgical expertise

Increased investment in specialist thoracic surgical expertise can lead to a significant rise in the lung cancer resection rate, based on data from England between 2008 and 2009 that was presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

In England, lung cancer resection is less common than in other countries, and is performed by both cardiothoracic and pure thoracic surgeons. Researchers tested the hypotheses that resection rate was related to the caseload and local provision of pure thoracic surgeons, and that expansion of thoracic surgery could increase the resection rate.

In 2008, 31 units provided the thoracic surgery service to 33 cancer networks comprising 174 trusts. Of these, 13 units (42%) had two or more pure thoracic surgeons. In 2009 this grew to 18 units (58%).

In 2008, there were 15,774 recorded cases of confirmed non-small cell lung cancer (NSCLC). Of these, 2,240 (14.2%) patients underwent surgical resection. In 2009, following the new consultant appointments, the number of histologically confirmed NSCLC increased by 13.8%, from 15,774 to 17,948 cases. The overall resection rate increased by 46% (from 14.2% to 20.7%).

In trusts where a pure thoracic surgeon was present in more than two-thirds of the lung cancer multidisciplinary team meetings, the NSCLC resection rate was significantly higher than those with lower attendance (median 14.7% vs 11.7%). Networks that experienced an expansion in their number of pure thoracic surgeons during this period experienced a significant and larger increase in resection rate than those who did not (median 66.3% vs 19%).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients